GNLX vs. IMMP, ATAI, NKTR, VTYX, ALDX, RANI, RZLT, ACRV, OMER, and AKBA
Should you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Immutep (IMMP), Atai Life Sciences (ATAI), Nektar Therapeutics (NKTR), Ventyx Biosciences (VTYX), Aldeyra Therapeutics (ALDX), Rani Therapeutics (RANI), Rezolute (RZLT), Acrivon Therapeutics (ACRV), Omeros (OMER), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical preparations" industry.
Immutep (NASDAQ:IMMP) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment.
Immutep has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, Genelux has a beta of -1.37, suggesting that its share price is 237% less volatile than the S&P 500.
In the previous week, Immutep and Immutep both had 3 articles in the media. Genelux's average media sentiment score of 0.42 beat Immutep's score of 0.25 indicating that Immutep is being referred to more favorably in the media.
Immutep received 301 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 72.43% of users gave Immutep an outperform vote.
2.3% of Immutep shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 3.1% of Immutep shares are held by insiders. Comparatively, 11.7% of Genelux shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Genelux's return on equity of 0.00% beat Immutep's return on equity.
Immutep has higher revenue and earnings than Genelux.
Immutep presently has a consensus price target of $8.50, suggesting a potential upside of 218.35%. Genelux has a consensus price target of $32.33, suggesting a potential upside of 1,318.13%. Given Immutep's higher probable upside, analysts clearly believe Genelux is more favorable than Immutep.
Summary
Immutep beats Genelux on 7 of the 13 factors compared between the two stocks.
Get Genelux News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
